{"filing":{"accession_number":"0001759425-26-000047","cik":"0001759425","ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-02","primary_document":"mirm-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm"},"events":[{"id":31842,"run_id":29240,"accession_number":"0001759425-26-000047","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the appointment of Rob Myers, M.D., as Chief Medical Officer effective September 21, 2026, to succeed Joanne Quan, M.D. While the section also describes Dr. Quan's departure and associated severance arrangements, the principal announced action is the appointment of a new CMO to a named executive officer role. The appointment of a C-suite executive is material to investors assessing company leadership and continuity.","company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34856,"accession_number":"0001759425-26-000047","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Rob Myers, M.D., as Chief Medical Officer effective September 21, 2026, to succeed Joanne Quan, M.D. While the section also describes Dr. Quan's departure and associated severance arrangements, the principal announced action is the appointment of a new CMO to a named executive officer role. The appointment of a C-suite executive is material to investors assessing company leadership and continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:35:51.321006+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34856,"accession_number":"0001759425-26-000047","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Rob Myers, M.D., as Chief Medical Officer effective September 21, 2026, to succeed Joanne Quan, M.D. While the section also describes Dr. Quan's departure and associated severance arrangements, the principal announced action is the appointment of a new CMO to a named executive officer role. The appointment of a C-suite executive is material to investors assessing company leadership and continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:35:51.321006+00:00","company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","filing_date":"2026-09-08"}]}